Innovation Articles

  1. Targeting Underlying Biology: Novel Combination Therapies For Chronic Disease 1/26/2026

    Combination therapies that incorporate cannabinoids and psychedelics signal an important shift in how complex chronic diseases are being approached. 

  2. Schrödinger's Equation Turns 100: How Quantum Chemistry Is Improving Drug Discovery 1/23/2026

    On January 26th, 2026 as we celebrate this centennial milestone of Schrödinger’s Equation, it’s worth asking: What does quantum mechanics mean for drug discovery and biomolecular simulations?

  3. Annual Reflections And Predictions From The Editors' Roundtable 1/6/2026

    Understanding the full scope of the life science industry has never been more critical. Ray Dogum, Chief Editor of Drug Discovery Online, joins the Life Science Connect Editors’ Roundtable on a special episode of Better Biopharma podcast.

  4. Engineering Therapeutics With A Structural Approach 12/30/2025

    Faraz A. Choudhury, CEO of Immuto Scientific, discusses target proteins and their adoption of disease-specific conformations that could increase how therapeutics discriminate between diseased and healthy tissues.

  5. Room For Improvement: Reformulating Existing Therapeutics 12/30/2025

    We caught up with Jed Litwiniuk, CEO, and Uwe Tigör, CMO, to talk about Auxilius Pharma’s work to improve and reformulate a treatment for chronic stable angina pectoris.

  6. The Unlikely Weapon Against Fentanyl: Your Immune System 12/23/2025

    ARMR Sciences Inc. has developed a vaccine designed with a novel adjuvant, dmLT, to neutralize fentanyl in the bloodstream before it reaches the central nervous system and binds to μ-opioid receptors (MORs). 

  7. 2025's Top 5 Drug Discovery Highlights And How To Stay Ahead In 2026 12/15/2025

    Drug Discovery Online's 2025 Top 5 most consequential shifts affecting this rapidly evolving field, including NAMs, AI, Individualized Therapies, Innovating China, and Early-stage Funding Volatility.

  8. GO‑4 Drug Combo Offers New Hope for Treating Late-Stage BRCA/PALB2-Mutated Cancers 11/24/2025

    General Oncology’s GO‑4 is an investigational product combining melphalan, BCNU, hydroxocobalamin, and ascorbic acid. The company's CEO, Jeff Glazier shared how the combo is designed to shut down DNA repair and resensitize hard‑to‑treat tumors to chemotherapy for patients with advanced pancreatic or breast cancer.

  9. Live Insights: 45% Believe The NAMs Industry Should Expand Pre-Competitive Data Sharing Programs 11/13/2025

    According to a recent poll, 45% of participants believe the NAMs industry should expand pre-competitive consortia by sharing validation data and best practices to reduce duplication and accelerate acceptance. Experts Zahar Nahle, Ph.D. and Samantha Atkins, Ph.D. share their insights.

  10. OpenFold3 Released: Redefining The Limits Of Protein Prediction Models 11/4/2025

    OpenFold3, a biomolecular structure prediction model based on AlphaFold3 was recently released by the OpenFold Consortium, a non-profit AI R&D organization.